DeutschNewstral
Article
wsj.com on 2016-08-18 00:10
Court Says Pfizer's Biosimilar of J&J's Remicade Doesn't Infringe Patent
Related news
Patent for J&J's Remicade invalidatedThe Salt Lake Tribune
Janssen and Celltrion: Remicade Biosimilar Patent Dancejdsupra.com
FDA approves biosimilar competition for J&J's Remicade drugbizjournals.com- J&J and Pfizer Settle Remicade Biosimilar Antitrust Suitjdsupra.com
- An Inflectra Update -- Pfizer Announces Launch of REMICADE® Biosimilarjdsupra.com
- Merck launches biosimilar version of J&J blockbuster Remicadebizjournals.com
- Remicade Biosimilar Closer To Approval, But Patent Dance Goes Onjdsupra.com
FDA approves 1st cheaper version of J&J's top drug Remicadedothaneagle.com
Patent for J&J’s Remicade invalidated, cheaper version loomsreviewtimes.com
If Pfizer's Right, Hospira Biosimilar Gold Rush Begins This WeekForbes- Biosimilars Update -- Pfizer's Proposed Epogen®/Procrit® Biosimilar Recommended for Approvaljdsupra.com
- Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilarjdsupra.com
- J&J: Despite Biosimilar Competition, Remicade® Retains Approximately 94% of Infliximab Volume Sharejdsupra.com
- New Use Patent for Janssen’s REMICADE valid and infringed by Hospira’s biosimilar INFLECTRAjdsupra.com
- Janssen Seeks Injunction Against Remicade Biosimilar Based On Cell Culture Patentjdsupra.com
- Judge Grants Gilead Motion To Invalidate Remicade Patent For Obviousness-Type Double Patentingjdsupra.com
- AbbVie and Pfizer Settle Adalimumab Biosimilar Patent Disputesjdsupra.com
- Celltrion's Proposed REMICADE® Biosimilar Recommended for Approvaljdsupra.com
- FDA Approves Inflectra - Celltrion's REMICADE® Biosimilarjdsupra.com
- Pfizer's Canadian partner sues Arbutus Biopharma in Covid-19 vaccine patent disputebizjournals.com